(ENOV) Enovis - Ratings and Ratios
Orthopedic, Surgical, Imaging, Bracing, Rehab
ENOV EPS (Earnings per Share)
ENOV Revenue
Description: ENOV Enovis
Enovis Corp (NYSE:ENOV) is a US-based healthcare equipment company. The quarterly tax provision data suggests that the companys financial performance is being closely monitored. As a healthcare equipment provider, Enovis Corp operates in a sector driven by demographic trends, regulatory changes, and technological advancements.
Key economic drivers for Enovis Corp include the growing demand for healthcare services due to an aging population, advancements in medical technology, and changes in healthcare policies. The companys performance is likely influenced by its ability to innovate and adapt to these changes. Key Performance Indicators (KPIs) to watch include revenue growth, operating margins, and return on equity (ROE), which is currently negative at -32.57%, indicating potential underlying issues that need to be addressed.
The companys market capitalization stands at $1.625 billion, with a forward Price-to-Earnings (P/E) ratio of 9.27, suggesting that investors have certain expectations for future earnings growth. The high beta of 1.808 indicates that ENOVs stock price is relatively volatile compared to the broader market, which may be a concern for risk-averse investors.
To improve its financial health, Enovis Corp may need to focus on enhancing its product portfolio, optimizing its operational efficiency, and navigating the complex regulatory landscape of the healthcare equipment industry. By addressing these areas, the company can potentially improve its profitability and deliver value to shareholders. Investors should closely monitor the companys progress on these fronts and adjust their investment decisions accordingly.
ENOV Stock Overview
| Market Cap in USD | 1,753m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2008-05-08 |
ENOV Stock Ratings
| Growth Rating | -71.5% |
| Fundamental | 41.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -34.0% |
| Analyst Rating | 4.55 of 5 |
ENOV Dividends
Currently no dividends paidENOV Growth Ratios
| Growth Correlation 3m | -9.6% |
| Growth Correlation 12m | -82.8% |
| Growth Correlation 5y | -81.4% |
| CAGR 5y | -13.82% |
| CAGR/Max DD 3y | -0.23 |
| CAGR/Mean DD 3y | -0.59 |
| Sharpe Ratio 12m | -1.47 |
| Alpha | 0.00 |
| Beta | 0.981 |
| Volatility | 49.82% |
| Current Volume | 1671.7k |
| Average Volume 20d | 908.2k |
| Stop Loss | 32 (-4%) |
| Signal | 1.51 |
Piotroski VR‑10 (Strict, 0-10) 3.5
| Net Income (-827.5m TTM) > 0 and > 6% of Revenue (6% = 131.4m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -1.57pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 32.53% (prev 34.21%; Δ -1.68pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 188.1m > Net Income -827.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.25 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (56.8m) change vs 12m ago 3.53% (target <= -2.0% for YES) |
| Gross Margin 59.46% (prev 55.03%; Δ 4.43pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 41.85% (prev 35.17%; Δ 6.68pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -19.39 (EBITDA TTM -460.1m / Interest Expense TTM 38.6m) >= 6 (WARN >= 3) |
Altman Z'' -0.47
| (A) 0.14 = (Total Current Assets 1.28b - Total Current Liabilities 568.2m) / Total Assets 5.02b |
| (B) -0.07 = Retained Earnings (Balance) -375.7m / Total Assets 5.02b |
| (C) -0.14 = EBIT TTM -748.7m / Avg Total Assets 5.23b |
| (D) -0.19 = Book Value of Equity -452.9m / Total Liabilities 2.44b |
| Total Rating: -0.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 41.29
| 1. Piotroski 3.50pt = -1.50 |
| 2. FCF Yield -2.15% = -1.08 |
| 3. FCF Margin -3.07% = -1.15 |
| 4. Debt/Equity 0.55 = 2.35 |
| 5. Debt/Ebitda -3.08 = -2.50 |
| 6. ROIC - WACC -23.66% = -12.50 |
| 7. RoE -29.85% = -2.50 |
| 8. Rev. Trend 96.34% = 7.23 |
| 9. EPS Trend 58.75% = 2.94 |
What is the price of ENOV shares?
Over the past week, the price has changed by +6.83%, over one month by +12.76%, over three months by +3.32% and over the past year by -21.58%.
Is Enovis a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ENOV is around 26.85 USD . This means that ENOV is currently overvalued and has a potential downside of -19.42%.
Is ENOV a buy, sell or hold?
- Strong Buy: 7
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ENOV price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 52.2 | 56.7% |
| Analysts Target Price | 52.2 | 56.7% |
| ValueRay Target Price | 29.1 | -12.5% |
Last update: 2025-09-05 04:41
ENOV Fundamental Data Overview
CCE Cash And Equivalents = 44.1m USD (Cash And Short Term Investments, last quarter)
P/E Forward = 8.673
P/S = 0.8004
P/B = 0.6797
P/EG = 1.8989
Beta = 1.808
Revenue TTM = 2.19b USD
EBIT TTM = -748.7m USD
EBITDA TTM = -460.1m USD
Long Term Debt = 1.37b USD (from longTermDebt, last quarter)
Short Term Debt = 43.1m USD (from shortTermDebt, last quarter)
Debt = 1.42b USD (Calculated: Short Term 43.1m + Long Term 1.37b)
Net Debt = 1.42b USD (from netDebt column, last quarter)
Enterprise Value = 3.13b USD (1.75b + Debt 1.42b - CCE 44.1m)
Interest Coverage Ratio = -19.39 (Ebit TTM -748.7m / Interest Expense TTM 38.6m)
FCF Yield = -2.15% (FCF TTM -67.2m / Enterprise Value 3.13b)
FCF Margin = -3.07% (FCF TTM -67.2m / Revenue TTM 2.19b)
Net Margin = -37.79% (Net Income TTM -827.5m / Revenue TTM 2.19b)
Gross Margin = 59.46% ((Revenue TTM 2.19b - Cost of Revenue TTM 887.7m) / Revenue TTM)
Tobins Q-Ratio = -6.90 (set to none) (Enterprise Value 3.13b / Book Value Of Equity -452.9m)
Interest Expense / Debt = 0.66% (Interest Expense 9.29m / Debt 1.42b)
Taxrate = 21.0% (US default)
NOPAT = -748.7m (EBIT -748.7m, no tax applied on loss)
Current Ratio = 2.25 (Total Current Assets 1.28b / Total Current Liabilities 568.2m)
Debt / Equity = 0.55 (Debt 1.42b / last Quarter total Stockholder Equity 2.58b)
Debt / EBITDA = -3.08 (Net Debt 1.42b / EBITDA -460.1m)
Debt / FCF = -21.08 (Debt 1.42b / FCF TTM -67.2m)
Total Stockholder Equity = 2.77b (last 4 quarters mean)
RoA = -16.48% (Net Income -827.5m, Total Assets 5.02b )
RoE = -29.85% (Net Income TTM -827.5m / Total Stockholder Equity 2.77b)
RoCE = -18.06% (Ebit -748.7m / (Equity 2.77b + L.T.Debt 1.37b))
RoIC = -18.10% (NOPAT -748.7m / Invested Capital 4.14b)
WACC = 5.56% (E(1.75b)/V(3.17b) * Re(9.63%)) + (D(1.42b)/V(3.17b) * Rd(0.66%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 93.13 | Cagr: 0.44%
Discount Rate = 9.63% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -67.2m)
EPS Correlation: 58.75 | EPS CAGR: 11.20% | SUE: 2.17 | # QB: True
Revenue Correlation: 96.34 | Revenue CAGR: 15.06%
Additional Sources for ENOV Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle